Adcendo seeks to develop antibody-drug conjugates to create new medicines for cancer patients with a significant unmet need.
The company was founded in 2017 in Copenhagen, as a spin-out from The Finsen Laboratory of Rigshospitalet and the University of Copenhagen.
The company was founded in 2017 in Copenhagen, as a spin-out from The Finsen Laboratory of Rigshospitalet and the University of Copenhagen.
Location: Denmark, Capital Region of Denmark, Copenhagen
Employees: 11-50
Total raised: $361.66M
Founded date: 2017
Investors 3
| Date | Name | Website |
| - | RA Capital... | racap.com |
| 01.01.2025 | TCG Crosso... | tcgcrossov... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 25.11.2024 | Series B | $135M | - |
| 29.05.2024 | Series A | $17.3M | - |
| 04.04.2023 | Series A | $89.55M | - |
| 12.01.2022 | Series A | $57.95M | - |
| 29.04.2021 | Series A | $61.86M | Novo Holdi... |
Mentions in press and media 20
| Date | Title | Description |
| 24.03.2026 | DualityBio (9606.HK) Announces 2025 Annual Results | HONG KONG, March 24, 2026 /PRNewswire/ -- Duality Biotherapeutics, Inc. (Hong Kong Stock Exchange Code: 09606.HK, hereinafter referred to as "DualityBio" or the "Company"), a leading global clinical-stage innovative biop... |
| 19.10.2025 | Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced... | AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs Promising antitumor activity was observed in... |
| 25.11.2024 | Novo Holdings-backed Adcendo secures $135M for ADC pipeline | Adcendo is adding $135 million to its arsenal, money that will go toward launching several antibody-drug conjugate (ADC) candidates into the clinic. California-based investor TCGX led the oversubscribed series B financing, with new investor... |
| 25.11.2024 | Adcendo Closes $135M Series B Financing | Adcendo, a Copenhagen, Denmark-based biotech company focused on the development of ADCs for the treatment of cancers with a high unmet medical need, raised $135M in Series B funding. The round was led by TCGX, with participation from new in... |
| 29.05.2024 | Adcendo Raises €16M; Extends Series A to €98M | Adcendo, a Copenhagen, Denmark-based biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers, raised additional €16M in additional Series A extension funding. The round, which ... |
| 14.04.2023 | Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting | Copenhagen, Denmark, 13 April, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, will be presenting nove... |
| 04.04.2023 | Adcendo ApS Announces Extension of Series A financing to 82M EUR toEnsure Broad Development of its First-in-class ADC Pipeline | Copenhagen, Denmark, April 4th, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, today announces the su... |
| 04.04.2023 | Adcendo ApS Announces Extension of Series A Financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline | Series A Financing extension led by Pontifax Venture Capital and existing investors Novo Holdings and Ysios Capital, raising an additional 31M EUR Funds will be used to ensure broad pan-sarcoma development of lead ADC asset uPARAP and to fu... |
| 04.04.2023 | Over DKK 3 billion (USD 413 million) raised by BioInnovation Institute portfolio companies to date | Portfolio company Adcendo Aps, today announces extension of Series A financing to 82M EUR. BII publishes its 2022 Impact Report outlining the success of its portfolio companies in the past year. BII's ambition is to support early-stage life... |
| 04.04.2023 | Ysios Capital’s portfolio company Adcendo announces extension of Series A financing to 82M€ to ensure broad development of first-in-class ADC pipeline | 04/04/2023 Nota de prensa YSIOS CAPITAL’S PORTFOLIO COMPANY ADCENDO ANNOUNCES EXTENSION OF SERIES A FINANCING TO 82M€ TO ENSURE BROAD DEVELOPMENT OF FIRST-IN-CLASS ADC PIPELINE Adcendo ApS (“Adcendo”), a biotech company focused on the de... |
Show more